The Online Investor
OLI Premium
Contrarian Outlook
Stock Option Ideas
Preferred Stock Newsletter

Slideshow Secondary Stock Offerings

By The Online Investor Staff, updated Tue., Jan. 21, 4:14 PM

Slide #17. Intra-Cellular Therapies, Inc. Secondary Offering

Company: Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)
Date announced: 1/6/2020
Shares Offered: 10,000,000
Date of Pricing: 1/7/2020
Price Per Share: $29.50
Secondary Offering Details: Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company, today announced that it has commenced an underwritten public offering of 10,000,000 shares of its common stock. In connection with the offering, Intra-Cellular Therapies intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering. All of the shares in the offering will be sold by Intra-Cellular Therapies. -updated 1/7- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company, today announced the pricing of its previously announced underwritten public offering of 10,000,000 shares of its common stock at a public offering price of $29.50 per share. All of the shares in the offering will be sold by Intra-Cellular Therapies, with gross proceeds to Intra-Cellular Therapies expected to be $295 million from the offering of an aggregate of 10,000,000 shares before deducting underwriting discounts and commissions and offering expenses. Intra-Cellular Therapies has granted the underwriters a 30-day option to purchase up to an additional 1,500,000 shares on the same terms and conditions. The expected net proceeds to Intra-Cellular Therapies referenced above do not include any net proceeds that Intra-Cellular Therapies would receive if the underwriters exercise such option. The offering is expected to close on January 10, 2020, subject to customary closing conditions.

Intra-Cellular Therapies is a biopharmaceutical company focused on the discovery and clinical development of small molecule drugs that address medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system. Co.'s primary product candidate, Lumateperone is for the treatment of acute and residual schizophrenia, and for the treatment of bipolar disorder, including bipolar depression. Co.'s pipeline also includes preclinical programs that are focused on developing drugs for the treatment of schizophrenia, Parkinson's disease, Alzheimer's disease and other neuropsychiatric and neurodegenerative disorders.

ITCI SEC Filing Email Alerts Service

Open the ITCI Page at The Online Investor »

Company Name:  Intra-Cellular Therapies Inc
Sector:  Drugs & Pharmaceuticals
Number of ETFs Holding ITCI:  31
Total Market Value Held by ETFs:  $170.82M
Total Market Capitalization:  $1.45B
% of Market Cap. Held by ETFs:  11.77%

Open the ITCI Page at The Online Investor (in a new window) »

January 21, 2020    4:14 PM Eastern
Quotes delayed 20 minutes

Strong Buy (4.00 out of 4)
90th percentile
(ranked higher than approx. 90% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Secondary Stock Offerings | | Copyright © 1998 - 2020, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.